IRIS
SACCA', FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.449
EU - Europa 4.632
NA - Nord America 4.235
SA - Sud America 834
AF - Africa 153
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
Totale 15.308
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.045
SG - Singapore 2.848
RU - Federazione Russa 2.255
CN - Cina 1.232
IT - Italia 921
BR - Brasile 674
HK - Hong Kong 557
VN - Vietnam 397
DE - Germania 322
NL - Olanda 279
GB - Regno Unito 158
FI - Finlandia 151
UA - Ucraina 150
IN - India 118
CA - Canada 98
IE - Irlanda 97
FR - Francia 86
AR - Argentina 70
KR - Corea 63
MX - Messico 63
ZA - Sudafrica 51
CI - Costa d'Avorio 45
BD - Bangladesh 41
AT - Austria 34
PL - Polonia 33
SE - Svezia 31
IQ - Iraq 29
JP - Giappone 28
EC - Ecuador 27
ES - Italia 24
CO - Colombia 18
ID - Indonesia 18
TR - Turchia 18
LT - Lituania 15
PK - Pakistan 13
VE - Venezuela 13
CL - Cile 11
CZ - Repubblica Ceca 10
EG - Egitto 10
MA - Marocco 10
AE - Emirati Arabi Uniti 9
BG - Bulgaria 9
IR - Iran 9
BO - Bolivia 8
DO - Repubblica Dominicana 8
BE - Belgio 7
CH - Svizzera 7
KE - Kenya 7
PT - Portogallo 7
PY - Paraguay 7
SA - Arabia Saudita 7
NP - Nepal 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
JO - Giordania 5
TN - Tunisia 5
AL - Albania 4
EE - Estonia 4
KZ - Kazakistan 4
RO - Romania 4
RS - Serbia 4
TH - Thailandia 4
BH - Bahrain 3
GR - Grecia 3
IL - Israele 3
MK - Macedonia 3
PA - Panama 3
PH - Filippine 3
UY - Uruguay 3
ZW - Zimbabwe 3
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BN - Brunei Darussalam 2
BW - Botswana 2
BZ - Belize 2
DK - Danimarca 2
DZ - Algeria 2
ET - Etiopia 2
EU - Europa 2
GF - Guiana Francese 2
GT - Guatemala 2
HN - Honduras 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LB - Libano 2
MN - Mongolia 2
MT - Malta 2
MU - Mauritius 2
MY - Malesia 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
UG - Uganda 2
AD - Andorra 1
AP - ???statistics.table.value.countryCode.AP??? 1
BY - Bielorussia 1
CR - Costa Rica 1
Totale 15.279
Salva come PNG Salva come JPEG
Città #
Singapore 1.380
Chandler 604
Moscow 580
Hong Kong 556
Ashburn 410
Beijing 380
Hefei 348
Santa Clara 247
Amsterdam 240
Naples 170
Millbury 135
Ho Chi Minh City 129
Los Angeles 123
Dallas 84
Nanjing 81
Munich 80
Princeton 80
Boston 73
Des Moines 73
Napoli 73
Hanoi 71
Buffalo 67
Redondo Beach 63
São Paulo 63
Seoul 62
New York 60
Seattle 59
Milan 54
Turku 49
Lawrence 46
The Dalles 46
Wilmington 42
Jacksonville 40
Cava De' Tirreni 38
Dong Ket 38
Nuremberg 35
Rome 34
Chicago 33
London 33
Nola 33
Norwalk 32
Toronto 32
Warsaw 30
Helsinki 29
Mexico City 27
Montreal 27
Houston 26
Ottawa 26
Denver 25
Johannesburg 25
Orem 25
Frankfurt am Main 22
Tianjin 22
Tokyo 22
Dearborn 21
Pune 21
Stockholm 21
Bollate 20
San Jose 20
Poplar 18
Belo Horizonte 17
Haiphong 17
Nanchang 17
Brooklyn 16
Da Nang 16
Dublin 16
Chennai 15
Rio de Janeiro 15
Ankara 14
Querétaro 14
Redwood City 14
Vienna 14
Atlanta 13
Biên Hòa 13
Manchester 13
Baghdad 12
Changsha 12
Curitiba 12
Düsseldorf 12
Jiaxing 12
Leawood 12
Mumbai 12
San Francisco 12
Torre Annunziata 12
Hebei 11
Lappeenranta 11
Phoenix 11
San Mateo 11
Woodbridge 11
Bexley 10
Boardman 10
Columbus 10
Falkenstein 10
Latina 10
Washington 10
Brasília 9
Giugliano in Campania 9
Guayaquil 9
Hải Dương 9
Ninh Bình 9
Totale 7.795
Salva come PNG Salva come JPEG
Nome #
A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. 160
Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit. 148
Modifications of resting state networks in spinocerebellar ataxia type 2 146
Ataxia-myoclonus syndrome due to a novel homozygous ATP13A2 mutation 146
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 144
Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study 144
A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients 137
GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response 136
Ataxia with oculomotor apraxia type 1 in southern italy: late onset and variable phenotype. 135
A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. 135
Vascular smooth muscle cell dysfunction in patients with migraine. 133
Multiple hormone deficiency syndrome in heart failure with preserved ejection fraction 133
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 133
Cognitive and functional connectivity alterations in Friedreich's ataxia 133
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 130
Emotion Recognition and Psychological Comorbidity in Friedreich’s Ataxia 130
Cerebellum and cognition in Friedreich ataxia: a voxel-based morphometry and volumetric MRI study 130
Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia 129
Benign hereditary chorea: clinical and neuroimaging features in an Italian family. 128
Pathological laughter as onset symptom in atypical parkinsonisms 128
Ofatumumab versus Teriflunomide in Multiple Sclerosis 127
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 126
Long-term therapy with miglustat and cognitive decline in the adult form of Niemann-Pick disease type C: a case report 126
Dimethyl Fumarate Mediates Nrf2-dependent Mitochondrial Biogenesis in Mice and Humans 125
The C-Terminal Cross-linked Telopeptide of Type I Collagen (CTX-I) as a Potential Cardiomyopathy Biomarker in Friedreich Ataxia Patients 123
Rationale and protocol of a double-blind, randomized, placebo-controlled trial to test the efficacy, safety, and tolerability of dimethyl fumarate in Friedreich Ataxia (DMF-FA-201) 123
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 123
The use of medical-grade cannabis in patients non-responders to Nabiximols 123
Dural sinus collapsibility, idiopathic intracranial hypertension, and the pathogenesis of chronic migraine 122
Variable phenotype in a P102L Gerstmann-Straussler-Scheinker Italian family 121
Recombinant human erythropoietin increasesfrataxin protein expression without increasing mRNA expression 121
Be aware of Wolfram syndrome when examining ataxic patients 121
Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis 121
A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results. 120
Multiple hormone deficiencies in chronic heart failure 120
Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chronic heart failure 118
Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection 118
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 118
‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab 118
Very late onset in ataxia oculomotor apraxia type I. 117
Chronic Pachymeningitis: a case of neurosyphilis with spastic paraparesis. 117
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 117
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 116
Aprataxin 115
The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis. 115
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 115
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 115
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis 115
A real-world study of alemtuzumab in a cohort of Italian patients 114
Ataxia with oculomotor apraxia type 1 in Southern Italy: late onset and variable phenotype 114
Ataxia with oculomotor apraxia type 2: a clinical, pathologic, and genetic study 114
Novel mutation of SACS gene in a Spanish family with autosomal recessive spastic ataxia 114
Safety and feasibility of upper limb cardiopulmonary exercise test in Friedreich ataxia 114
Frontal defect contribution to decreasing of body mass index in Parkinson's disease patients 112
Application of the p9NORM correction method to timed neuropsychological tests in Parkinson's disease and multiple system atrophy. 112
Adult normative values for the PATA Rate Test 111
Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia 111
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial 110
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. 110
A randomized clinical trial of lithium in multiple system atrophy. 110
Consistent improvement with eculizumab across muscle groups in myasthenia gravis 110
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 110
Stability of erythropoietin repackaging in polypropylene syringes for clinical use 109
Peripheral markers of autophagy in polyglutamine diseases 109
Longitudinal study of a cohort of MSA-C patients in South Italy: survival and clinical features 109
Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study 108
The flavor test is a sensitive tool in identifying the flavor sensorineural dysfunction in Parkinson's disease 107
Predictors of survival in spinocerebellar ataxia type 2 population from Southern Italy. 107
Variable phenotype in a P102L Gerstmann-Sträussler-Scheinker Italian family. 105
Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests 104
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 103
Mobitz type I and II atrioventricular blocks during fingolimod therapy 103
Myocardial (123)I-metaiodobenzylguanidine scintigraphy in patients with homozygous and heterozygous parkin mutations 103
The “crab sign”: an imaging feature of spinocerebellar ataxia type 48 103
Insulin Sensitivity and Early-Phase Insulin Secretion in Normoglycemic Huntington's Disease Patients 102
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 101
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 101
A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine 100
Metabolic Ataxias in Adults. 100
Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). 100
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 100
Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation. 98
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 98
SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. 97
The Multiple Faces of Spinocerebellar Ataxia type 2 97
Friedreich ataxia: 150 years of bench and bedside studies 97
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 97
A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A 95
A Review of Brain and Pituitary Gland MRI Findings in Patients with Ataxia and Hypogonadism 95
Eculizumab improves fatigue in refractory generalized myasthenia gravis 94
Othello syndrome in Parkinson's disease: a systematic review and report of a case series 94
Screening for RFC-1 pathological expansion in late-onset ataxias: a contribution to the differential diagnosis. 94
Degenerative and acquired sporadic adult onset ataxia 92
The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families 92
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 92
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 91
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 91
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 91
Functional MRI signal fluctuations highlight altered resting brain activity in Huntington’s disease 90
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 90
Totale 11.419
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.698
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.698
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021303 0 0 0 0 0 97 30 25 39 17 47 48
2021/2022830 16 10 10 4 12 54 18 44 94 72 191 305
2022/20231.391 151 124 47 108 153 167 12 108 214 233 53 21
2023/2024934 30 125 108 51 44 100 5 150 12 22 198 89
2024/20255.061 210 221 37 82 166 247 665 318 302 488 1.894 431
2025/20265.905 1.037 817 1.045 961 1.648 397 0 0 0 0 0 0
Totale 15.700